- About us
- Strategies
-
Portfolio
- Beacon Therapeutics
- Amphista Therapeutics
- Azafaros
- AIRNA
- AM-Pharma
- Allecra Therapeutics
- Anaveon
- AAVantgarde Bio
- Achilles Therapeutics
- Bicycle Therapeutics
- BioInvent
- Calluna Pharma
- Capstan Therapeutics
- catalYm
- CellCentric
- Citryll
- Complement Therapeutics
- Dyne Therapeutics
- eeden
- enGene
- Engrail Therapeutics
- Enterprise Therapeutics
- F2G
- Granite Bio
- Kynexis
- LoQus23 Therapeutics
- MapLight Therapeutics
- Marea Therapeutics
- Mestag Therapeutics
- Mosanna Therapeutics
- Navigator Medicines
- NeRRe Therapeutics
- NewAmsterdam Pharma
- Noema Pharma
- NorthSea Therapeutics
- Novameat
- Numab
- OMEICOS Therapeutics
- Orbis Medicines
- Pheon Therapeutics
- Precirix
- Prilenia Therapeutics
- Progentos Therapeutics
- Purespring Therapeutics
- Rectify Pharma
- Replimune
- RyCarma
- Seamless Therapeutics
- Solasta Bio
- SynOx Therapeutics
- Tessellate Bio
- VectorY
- Verdiva Bio
- Vor Bio
- Abiomed
- Acadia Pharmaceuticals
- Accelerated Technologies
- Acorda Therapeutics
- Aiolos Bio
- Akarna Therapeutics
- Alantos Pharmaceuticals
- Amakem
- AMT
- Ardana
- arGEN-X
- Argos Therapeutics
- Ario Pharma
- ARMGO Pharma
- Autonomic Technologies Europe
- Bioceros
- Biovex
- Bluebird Bio
- Borean Pharma
- Cellnovo
- Circulite
- Curetis
- Cytheris
- Dezima Pharma
- Escalier Biosciences
- Exosome Diagnostics
- Flowmedica
- Forbion European Acquisition Corporation
- Fovea
- Galapagos
- gIcare pharma
- Glycart
- Gotham Therapeutics
- Gyroscope Therapeutics
- Hookipa Biotech
- Impella Cardiosystems
- Inflazome
- Insmed
- Inversago Pharma
- KaNDy Therapeutics
- Mariana Oncology
- Milestone Pharmaceuticals, Inc.
- Mitralign
- NovoGI
- Oxitope
- Oxular
- Oxyrane
- PanGenetics
- Pathway Medical Technologies
- Pieris Pharmaceuticals
- PneumRx
- Promedior
- Pulmagen Therapeutics
- Rigontec
- RSPR Pharma
- Sanifit
- Santaris Pharma
- Staten Biotechnology
- Transave
- uniQure
- VectivBio
- Versanis Bio
- X-Cell Medical
- Xention
- Prexton Therapeutics
- Genomines
- Ventures
- Growth
- BioEconomy
- Yellow Jersey Therapeutics
- Sparrow
- Expedition Therapeutics
- Elevara Medicines
- PACT
- Braveheart Bio
- Gate Bioscience
- Protego
-
Team
- Audrey Cacaly, MSc
- Carlo Incerti, MD
- Charlotte Koldeweij, MD, PhD
- Dirk Kersten
- Dmitrij Hristodorov, PhD
- Frank G. Holz, Prof
- Geert-Jan Mulder, MD
- Gijs van den Brink, MD, PhD
- Gilles van Tienderen, PhD
- Holger Reithinger, PhD
- Jasper Bos, PhD
- Jens Wendland, MD
- John Ford, PhD
- John J.P. Kastelein, MD PhD FESC
- John Montana, PhD, MRSA
- Jonathan McNeill, MD
- Kanay Khakhria, MD
- Luuk de Vries, PhD
- Marc-Olivier Turgeon, PhD
- Marco Boorsma, PhD
- Martien van Osch, MSc
- Mathias Vinther, PhD
- Matt Cooper, PhD
- Melanie de Almeida, PhD
- Michael Hayden, MBChB, PhD
- Morgan Haller, MSc
- Nanna Lüneborg, PhD, MBA
- Patrick Round, MD
- Patrick Vink, MD, MBA
- Peter Høngaard Andersen, dr. med.
- Philip Astley-Sparke, FSA
- Simon J Clark, Prof
- Regina Salvat, PhD
- Robbert van de Griendt, MSc
- Roberto Hofmann, PhD
- Rogier Rooswinkel, PhD
- Rory Gummerson
- Sander Slootweg, MSc
- Sander van Deventer, MD PhD
- Scott Friedman, MD
- Tim Lohoff, PhD
- Ton Logtenberg, PhD
- Vanessa Carle, PhD
- Vincent Loon, MSc
- Vincent van Houten, MSc
- Wouter Joustra, MSc
- Yigal M. Pinto, MD, PhD
- Cyril Lesser, MSc, LLM
- Devan Sequeira, MBA
- Stefan Oschmann
- Per Falholt
- Onno van de Stolpe, MSc
- Maximillien Souvereyns, MSc, MBA
- Liz Rodgers
- Joy Faucher
- Joseph Iwasyk, MSc
- Floor Saris, MSc
- Felix Güttersberger
- Feike Sijbesma
- Cees de Jong, MD, MBA
- Alexander Hoffmann
- Tineke Duijn
- Sharon Dirkse
- Olga Ziessen
- Marijana Stojanovic
- Danielle de Magalhães
- Chelle Tjabring
- Alicia Dortona
- Wilfred Kevelam
- Walter Schram, BEc, QC
- Stijn Jochemsen, MSc
- Silva Dezelan, PhD
- Sabina Osenberg, MSc
- Rachelle Young
- Patricia Vonk, MSc
- Pascal van Wees, MSc
- Maureen Wouters
- Machteld Groeneveld, LLM, EMBA
- Laura Asbjornsen, LLM, MBA
- Jennifer Fritzsche, MSc
- Iris Veldman, LLM
- Elisa Camorani
- Josh Brumm
- Marc van Voorst tot Voorst
- Francine MacLeod
- Nat Kolber
- Vivien Veninga
- Cerelia Caesar
- Dragana Dragusin
- Jon Edwards
- Carolin Lanfer
- Steen Riisgaard
- Sustainability
-
News & Insights
-
News
- IPEM Interview Sander Slootweg
- Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP
- Forbion Announces Fifth Exit from Forbion Growth Opportunities Fund II with the Sale of Capstan Therapeutics to AbbVie for USD 2.1 Billion
- FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
- Vor Bio Announces $175 Million Private Placement
- Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease
- Forbion co-leads $80 Million Series A Financing in Mosanna Therapeutics to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea
- Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform with Enhanced Artificial Intelligence Capabilities of Gefion Supercomputer
- Forbion co-leads $120 million investment in CellCentric to advance inobrodib for treating multiple myeloma
- Forbion co-leads € 132M Series B Oversubscribed Financing in Azafaros to Advance Phase 3 Clinical programs of innovative therapies in lysosomal storage disorders
- Forbion leads €18M Series A Financing in Textile Recycling Technology company EEDEN
- Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
- Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets
- Forbion co-leads $100 Million Series B Financing of Granite Bio
- Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
- RyCarma Therapeutics Appoints Elizabeth Tarka, M.D., as Chief Medical Officer
- Forbion Co-leads Oversubscribed $155 Million Series B Financing in AIRNA to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline
- VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer
- Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer
- Orbis Medicines Names Veteran R&D Leader Mikael Dolsten Board Chair
- Forbion Expands US Presence with the Appointment of Regina Salvat, PhD, as Principal in the Boston Office
- LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
- Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors
- Forbion BioEconomy Fund I surpasses €150 million target, raising €164.5 million with strong institutional LP support
- Forbion promotes Dirk Kersten to Managing Partner and strengthens US team
- Forbion Co-Leads over $410M Series A Financing to Launch Verdiva Bio, a Clinical-Stage Cardiometabolic Company Advancing Next-Generation Therapies
- CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab
- Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025
- RyCarma Therapeutics Announces New Leadership and Company Name, Introduces Program in Heart Failure
- Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles
- Noema Pharma Appoints Volker Knappertz, M.D., as Executive VicePresident of Research &Development
- Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
- VectorY Strengthens Leadership Team with appointment of Jim Scibetta as new CEO
- Forbion Welcomes Gijs van den Brink, MD, PhD. as Operating Partner
- Noema Pharma extends Series B financing round, closing at CHF 130 Million ($147 Million)
- CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature
- Citryll Raises Eur 85 Million Series B to Advance Novel Net-Targeting Therapy for Immune-Mediated Inflammatory Disorders
- Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform
- AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa
- Forbion, in collaboration with members of the EU Life Sciences ESG Knowledge Project release 2025 questionnaire
- Complement Therapeutics Appoints Dr Muhammad Ali Memon FRCOphth, as Chief Medical Officer
- Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
- Tessellate BIO Announces Appointment of Lara Boyd as Chief Business Officer
- Noema Pharma Announces First Patients Dosed in Phase 2b Study with Gemlapodect (NOE-105), a First-In-Class Investigational Therapy for Tourette Syndrome
- SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial
- AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy
- Forbion Policy for Responsible Investments 2024
- BioEconomy Policy for Responsible Investments 2024
- AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
- Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints
- Forbion raises in excess of €2 billion for two new funds
- Purespring Therapeutics raises £80/$105 million in Series B financing to transform the treatment of kidney diseases
- Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board
- AAVantgarde announces 3 oral presentations at the European Society of Gene & Cell Therapy 31st Annual Meeting in Rome
- Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases
- Forbion leads £35 million (c.$43 million) Series A financing in LoQus23 Therapeutics to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
- Forbion Head of Impact & ESG named as one of Top 50 Women in Sustainable Finance 2024
- Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
- Orbis Medicines & Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’
- AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
- Forbion Co-Leads €17.4m Oversubscribed Series A Financing of Novameat to accelerate and scale production capacity of plant-based meat
- F2G Announces $100 Million Financing to Advance Late-Stage Development and Commercialization of Novel Antifungal Drug Candidate Olorofim in the US
- Forbion Leads $14m Series A in SOLASTA Bio to advance development and commercialisation of first-in-class sustainable crop protection solutions
- Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference
- Forbion Impact & ESG Report 2023
- Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
- Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
- Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300
- Forbion Co-leads $100 Million Series A Funding in Navigator Medicines to Advance Development of Best-in-class antibody therapeutics for autoimmune diseases.
- Noema Pharma Announces Completion of Enrollment for GALENE Phase 2B Trial Evaluating NOE-101, a First-in-Class mGluR5 NAM, for Seizure Control in Tuberous Sclerosis Complex
- Forbion leads Oversubscribed $60 Million Financing in AIRNA to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic
- enGene Announces Appointment of Ron Cooper as Chief Executive Officer
- Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer
- Enterprise Therapeutics Doses First Person with Cystic Fibrosis in Phase 2 Trial for Novel Therapy ETD001
- Forbion Growth Opportunities Fund participates in $150M series D financing of CatalYm
- VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board
- Forbion Leads $170 Million Series B Funding in Beacon Therapeutics to Advance Development of Ophthalmic Gene Therapies
- Forbion Strengthens US Presence, Hiring Biotech Industry Leader and Opening Boston Office
- Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
- Forbion announces first close of its new BioEconomy Fund I: backing biotech-enabled companies aiming to impact the future of our planet
- Forbion co-leads $190 million Financing of Marea Therapeutics
- CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
- Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
- Forbion Announces $1.25 Billion Sale to Johnson & Johnson of Numab Therapeutics Subsidiary, Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis, Marking its Sixth Consecutive Billion-Dollar+ Exit
- Dyne Therapeutics Announces Closing of Public Offering of Common Stock & Full Exercise by Underwriters of Option to Purchase Additional Shares
- Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
- Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause
- Forbion leads $65 million Series A Financing of Progentos Therapeutics
- Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
- enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
- AAVantgarde presents the design of its innovative LUCE-1 trial for USH1B at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit
- Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer
- SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
- AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
- Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform
- Forbion co-leads $75m Series B Financing in SynOx Therapeutics
- Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024
- Prilenia Names Jina Swartz, M.D. Ph.D., as Chief Medical Officer
- Forbion Invests in Capstan Therapeutics with participation in $175M Oversubscribed Series B Financing
- Forbion co-leads oversubscribed $157M Series B Financing Round in Engrail Therapeutics
- Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
- NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
- Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease
- Forbion co-leads €26 million Seed Financing with launch of Orbis Medicines
- Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
- NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program
- enGene Announces Oversubscribed $200 Million Private Placement Financing
- NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
- ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies
- Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
- Forbion announces 75 million EUR Series A financing in Calluna Pharma
- Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™
- Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment
- VectorY appoints Khurem Farooq to Board of Directors
- Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Forbion portfolio company Aiolos Bio, Inc. (Aiolos) to be acquired by GSK for up to $1.4 billion
- CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists
- Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
- Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
- Complement Therapeutics Announces the Establishment of Medical Advisory Board
- Aiolos Bio Strengthens and Expands Leadership Team with Key Appointments
- Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled
- CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
- Complement Therapeutics Appoints Dr. Matthias Hebben, as Chief Technology Officer
- Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023
- Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with Geographic Atrophy
- AAVantgarde Appoints Dr. Peter K. Kaiser to the Board of Directors
- Forbion Leads €57 Million Series A Financing in Kynexis, a New Precision Therapeutics Biotech for Brain Diseases
- enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
- AAVantgarde Appoints Michael Heffernan as Chairman of its Board of Directors
- Forbion co-leads $245 million Series A financing of Aiolos
- Forbion leads $85M Series A Financing in Rampart Bioscience
- Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema
- Forbion Portfolio company Tessellate BIO emerges from stealth
- NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease
- Forbion Impact Report 2022
- Forbion Policy for Responsible Investments 2023
- AM-Pharma Announces Positive Clinical Data From Phase 1b Study Evaluating Ilofotase Alfa in Hypophosphatasia Patients
- Fierce Biotech - ‘The fundamentals are really strong’: Why investors are staying loyal to European biotech in 2023
- EUVC #223 - Podcast with Forbion Partner Juliette Audet
- NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
- Pharma deal making: a bright spot amid the gloom
- AAVantgarde Appoints Dr. Doug Kerr to the Board of Directors
- Oxular Announces Appointment of Mark Gaffney as Chief Executive Officer
- Forbion co-leads $175 million Series B financing of Mariana Oncology as first investment of Forbion Ventures Fund VI
- AMG Completes Investment in Forbion
- NewAmsterdam Pharma Announces Appointment of William “BJ” Jones as Chief Commercial Officer
- Forbion Portfolio Company Inversago Pharma to be acquired by Novo Nordisk
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
- Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer
- Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
- ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia
- Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
- Sifted - The 10 most active techbio investors in Europe
- Pheon Therapeutics enters into license agreement with Biocytogen Pharmaceuticals
- Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
- AMG Announces Partnership with Forbion
- Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions
- Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer
- OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study
- Complement Therapeutics Unveils State-of-the-Art Laboratory at Stevenage Bioscience Catalyst
- Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients
- BioInvent announces additional efficacy data from intravenous part of Phase 1/2 trial with BI-1206 in solid tumors
- Forbion co-leads €61 Million Series A Financing in AAVantgarde to Advance Two Therapeutic Programs into the Clinic
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
- Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
- Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
- enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies
- Forbion co-leads €40 million Series A in Dualyx
- Forbion appoints Silva Deželan, PhD as Head of Impact and ESG
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
- Forbion raises €1.35 billion across two funds
- Forbion co-leads €72 Million Series A Financing in Complement Therapeutics to Advance Novel Therapies Targeting Complement-Mediated Diseases
- NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
- Precision Financing
- VectorY Appoints Michael Wyzga as CFO and adds Jean Franchi to its Board of Directors
- Azafaros Appoints Chief Operating Officer and Head of Finance
- Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases
- Forbion co-leads CHF 103 million investment in Noema Pharma
- Life changing treatments for rare disease – a beacon of hope
- Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
- Rectify Pharmaceuticals Expands Clinical Drug Development Expertise with Board and SAB Appointments
- Complement Therapeutics Enrols First Patient in Non- interventional i-GAIN Study of People Diagnosed with Geographic Atrophy
- NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
- BIA Finance Report - Forbion named the most active non-UK investor
- Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema
- VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters
- NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
- Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress
- Azafaros Receives FDA’s IND Clearance and Fast Track Designation
- NorthSea Therapeutics appoints Morris J. Birnbaum to the Board
- Mestag Therapeutics appoints Prof. Ton Logtenberg as Chair
- F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections
- CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort
- Rectify Pharmaceutical Announces Publication of Trends in Molecular Medicine Review Article Highlighting the Therapeutic Potential of the ABC Transporter Superfamily
- OMEICOS Therapeutics Announces Expansion of OMT-28 Clinical Development Program into Primary Mitochondrial Diseases
- Replimune Announces Pricing of Public Offering
- Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
- Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease
- Oxitope Appoints Leading Interventional Cardiologist Gregg Stone to Advisory Board for Myocardial Reperfusion Injury
- NewAmsterdam Pharma Debuts as Publicly Traded Company
- Forbion Portfolio Company CatalYm Closes EUR 50 Million Series C Financing
- Forbion Portfolio Company Inversago named in Labiotech list of "The hottest private biotech companies in Canada"
- Angelika Amon Young Scientist Award for Forbion Fellow Melanie de Almeida, PhD
- VectorY Appoints Sander van Deventer as CEO and makes Key Appointments to its Leadership Team
- VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)
- MHRA awards Complement Therapeutics Innovation Passport for CTx001 to accelerate Gene Therapy for Geographic Atrophy
- F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with Olorofim
- AM-Pharma Provides Business Update and Outcome of Pre-Planned Interim Futility Analysis of Phase 3 Revival Study
- Inversago Pharma Raises $95 million CAD in Series C Financing
- VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)
- VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
- Forbion Policy for Responsible Investments 2022
- Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/Enmetazobactam Met Criteria for Superiority
- Bloomberg Europe Edition - Nordic VC Firms Expand to Listed Biotechs in Hunt for Bargains
- Forbion Co-leads $68m Investment in Newly Launched Antibody-Drug Conjugate Specialist Pheon Therapeutics
- Complement Therapeutics Announces the Establishment of its Clinical & Scientific Advisory Board
- CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the U.S.
- European Investor Sentiment Rebounds On Cell And Gene Therapy
- Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease
- Fierce Biotech Names Amphista Therapeutics as One of its “Fierce 15” Biotech Companies of 2022
- CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination
- Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- The 2022 PharmaVoice 100 - Legacy Leaders: Dr. Michael Hayden The CEO at Prilenia has an unwavering dedication to address the needs of HD patients and their families.
- CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CLT-002) at the 2022 ESMO Congress
- VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA
- NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib
- Complement Therapeutics Ltd announces appointment of Dr Dennis Keefe as Chief Scientific Officer
- Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim
- Precirix and Eckert & Ziegler sign agreement on Actinium-225 supply
- NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases
- Forbion appoints Dr. Peter Høngaard Andersen as Operating Partner and Dr. Matt Cooper as Venture Partner
- Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors
- Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- Venture Capital Journal - European VCs may be better prepared for a downturn than their US peers
- NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe
- Spotting Biotech Opportunities in a Changing Market - Commentary by Forbion General Partner Jasper Bos
- Beyond Biotech - the podcast from Labiotech
- Forbion General Partner Nanna Lüneborg, PhD, MBA proposed as new Board member of BioInvent
- Forbion Growth Opportunities Fund II leads USD 50 million placement of VectivBio
- Forbion announces first close of Forbion Growth Opportunities Fund II at €470 million
- Endpoints - Amidst a struggling IPO market, Forbion drums up half a billion in private cash for second late-stage fund
- Prilenia Announces Publication of Data Elucidating a Mechanism for Neuroprotective Potential of Pridopidine
- Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
- NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia
- Dr Michael Hayden MBChB, PhD interview with the Huntington's Disease Youth Organisation (HDYO)
- Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
- Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
- 400 Patients have been enrolled in AM-Pharma’s Pivotal Phase 3 Study of Ilofotase Alfa for the treatment of Sepsis-Associated Acute Kidney Injury
- SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
- Wie die Krise Life Sciences-Investoren beeinflusst und den M&A-Markt beflügelt
- Forbion appoints both Dr Ton Logtenberg and Dr Michael Hayden as Venture Partners
- Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target
- Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease
- Forbion co-leads EUR 80m Series B investment in Precirix to advance its pipeline of precision radiopharmaceuticals
- Biotech Stocks in “Total Eclipse” as Financial Pressures Mount
- Forbion strengthens its team with the appointments of Mathias Vinther and Vanessa Carle
- Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors
- CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
- NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with Atherosclerotic Cardiovascular Disease (ASCVD)
- BioWorld: Complement Therapeutics emerges from stealth with plan to take on untreatable eye disease
- Forbion and BGV announce EUR 5 million seed investment in Complement Therapeutics and appointment of Dr. Rafiq Hasan as CEO
- Late-stage investors see opportunity in the bear market
- Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference
- enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease
- Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis
- VectorY and Wageningen University sign strategic collaboration for the development of novel baculovirus-based AAV production technologies
- Lonza, Forbion, and BioGeneration Ventures Extend Collaboration to Add Development and Manufacturing Services of Small Molecules
- Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe
- Prilenia Announces Completion of Patient Enrollment Ahead of Schedule in the Pridopidine Arm of the HEALEY ALS Platform Trial
- Gyroscope Therapeutics to be acquired for up to $1.5 billion
- Forbion leads $35M Series B for ARMGO Pharma
- NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
- Forbion to lead oversubscribed CHF 110M Series B for Swiss immune-oncology company Anaveon
- Forbion closes the initial public offering of 11.0 million units of Forbion European Acquisition Corporation (FEAC) on the Nasdaq Global Market
- Forbion European Acquisition Corp. Announces Pricing of $110 Million Initial Public Offering
- uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
- Amphista Therapeutics Appoints Dr Martin Pass as CDO
- Prilenia Closes Oversubscribed $43 Million in Series B Financing Round
- Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy
- Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
- Forbion Portfolio Company Prilenia receives Fast Track Designation for Treatment of Huntington’s Disease
- Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity
- CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
- Interview with Sander Slootweg M&A Magazine (In Dutch)
- Gyroscope Therapeutics Announces Sanofi Investment of up to $60 Million
- Amphista Therapeutics Appoints CBO, Beverley Carr
- Oxitope-led consortium awarded prestigious Eurostars grant to develop new drugs for cardiovascular diseases
- Prilenia and Huntington Study Group Announce Completion of Patient Enrollment Ahead of Schedule in Global Phase 3 PROOF-HD Huntington’s Disease Clinical Trial
- Forbion Policy for Responsible Investments 2021
- Forbion Co-Leads New Investment in Rectify Pharmaceuticals Which Launches with $100m Series A Financing
- HMI Meets Sander Slootweg
- J&J Webinar with General Partner Dirk Kersten
- Forbion Portfolio company Covicept Therapeutics initiates a Phase 2 clinical trial of PJS-539 for the treatment of patients with COVID-19
- Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression
- CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
- Sustained-Release Steroid Options For DME Therapy
- Fierce Biotech Names Forbion Portfolio Company Mestag Therapeutics as one of its "Fierce 15" Biotech Companies 2021
- Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm
- Forbion launches portfolio company Oxitope Pharma focused on inflammatory, cardiovascular and fibrotic diseases
- Forbion Appoints Nanna Lüneborg as a General Partner
- Achilles Therapeutics Announces Grant of US and European Patents
- Forbion Leads €28.6million Seed Extension Financing for Mestag Therapeutics
- SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
- NewAmsterdam Pharma Reports Positive Results from Phase 2 Study of Oral Obicetrapib Demonstrating Over 50% LDL-c Lowering as an Adjunct to High-Intensity Statins
- SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
- FDA Grants Orphan Drug Designation for pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
- NeRRe Therapeutics raises £20 million in a Series B2 financing round
- AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board
- AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial
- Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer
- uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
- Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids
- Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001
- Forbion co-leads VectorY EUR 31 million seed financing
- enGene Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial
- Forbion’s Growth Opportunities Fund completes EUR 91 million Oversubscribed Series C Financing for Numab Therapeutics
- Forbion expands team with new General Partner
- Prilenia Achieves 25% Enrollment in its phase 3 HD trial and appoints Dr. Goldberg as CSO
- Replimune Appoints Tanya Lewis as Chief Development Operations Officer
- CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
- Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
- Forbion announces final close of Forbion Growth Opportunities Fund I at EUR 360 million (USD 428 million)
- Forbion Appoints Head of Communications
- Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorders
- Achilles Therapeutics Announces Pricing of Initial Public Offering
- Forbion’s Growth Opportunities Fund leads $148M Series C Financing for Gyroscope Therapeutics
- Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
- Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
- Forbion leads $37M financing for Oxular
- Launch of novel gene therapy company, VectorY, to develop innovative vectorized antibodies
- Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease
- Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
- uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer
- Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease
- Forbion invests USD 2.3M in seed financing of CoviCept Therapeutics, Inc.
- Forbion portfolio company, NewAmsterdam Pharma completes €160M Series A Funding for Phase 3 Development Program
- Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
- Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS
- NST: Positive Phase 2b ICONA interim results for icosabutate in NASH patients
- BioGeneration Ventures BGV IV fund closes at €140 million
- AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial
- Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China
- uniQure N.V. - uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
- Lonza, Forbion and BioGeneration Ventures Announce Collaboration for Development and Manufacture of Biologics for Portfolio Companies
- Forbion secures EUR 460 million for oversubscribed fifth fund
- uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
- uniQure N.V. - uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
- Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours
- Forbion invests in EUR 37M series A financing of SynOx Therapeutics
- NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline
- AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury
- CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients
- Replimune Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference
- Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
- uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
- uniQure Inc. - uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
- Prilenia Enrolls First Patients into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United States
- Allecra Therapeutics Announces Late-breaker Presentation of Phase 3 ALLIUM Trial with Cefepime-Enmetazobactam in cUTIs at IDWeek 2020
- AM-Pharma Appoints Chief Medical Officer and VP Manufacturing to Support Global Pivotal Trial in Sepsis-associated Acute Kidney Injury
- Replimune Releases Updated Corporate Presentation
- Replimune Appoints Tanya Lewis to the Board of Directors
- Forbion portfolio company, Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche
- Forbion portfolio company, Inflazome acquired by Roche
- Henk Schuring joins Prilenia as Chief Regulatory and Commercialization Officer
- Forbion leads US$35M Series B financing round for Inversago Pharma
- NewAmsterdam Pharma acquires Obicetrapib from Amgen
- Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002
- Forbion portfolio company, KaNDy Therapeutics, to be acquired by Bayer
- Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases
- Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
- Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer
- Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
- Forbion announces first close of Forbion Growth Opportunities Fund at EUR 185 million (USD 208 million)
- SNF472 Mechanism of Action data published in British Journal of Pharmacology
- Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer
- uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- Forbion leads $62.5m Series A fund raising for Prilenia Therapeutics
- Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens
- Sanifit Enhances Leadership Team with New Executive Appointments
- HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal of Infectious Diseases
- Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors
- AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI
- Inzomelid completes Phase I studies and shows positive results in the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)
- uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters
- Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections
- Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study
- Promedior Announces Completion of Acquisition by Roche
- First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis
- Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
- Forbion Appoints Dr. John Montana as Operating Partner
- KANDY THERAPEUTICS ANNOUNCES POSITIVE PHASE 2B DATA IN POST-MENOPAUSAL WOMEN WITH ITS LEAD NON-HORMONAL PRODUCT NT-814
- Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization
- NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic
- Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients
- Forbion Wins “VC firm of the Year” at the LSX’s LifeStars Awards
- Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche
- Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation
- Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)
- Inflazome Progresses Two Drugs Into Clinical Trials
- Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis
- Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer Patients
- Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
- Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
- Dyne Therapeutics announces appointment of Joshua Brumm as President and Chief Executive Office
- Pieris Pharmaceuticals and AstraZeneca Present Multiple Ascending Dose Phase 1b Data for Inhaled IL4-Rα Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress
- NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)
- Sanifit named as one of 2019’s “Fierce 15” biotechnology companies by FierceBiotech
- Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development
- Forbion Participates in £100m Series B Financing of Achilles Therapeutics
- OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer
- uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
- Forbion Portfolio Company, AM-Pharma Raises €116m to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury
- Sanifit announces €72.2M ($80.9M) financing in Spain's largest private biotech fundraise
- Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab
- Issued Patents in the U.S. and EU Cover RNA Construct Specifically Designed to Target Highly Toxic Exon1 Protein
- Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis
- Forbion Portfolio Companies Milestone and HOOKIPA Successfully List on the NASDAQ Stock Exchange
- Milestone Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
- uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
- uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting
- OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation
- Whale Watching - What a decade of change at Big Pharma taught us about corporate phenotypes
- HOOKIPA Pharma Announces Pricing of Initial Public Offering
- uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- Forbion analysis on European biotech landscape published in Nature Biotechnology
- Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
- Mapping the European startup landscape
- Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero
- Enterprise Therapeutics strengthens leadership team, appoints Amit D. Munshi as Non-Executive Chairman
- Data from SNF472 Phase 1b Clinical Trial published in British Journal of Clinical Pharmacology
- uniQure to Participate in Multiple Upcoming Industry Conferences
- uniQure Announces 2018 Financial Results and Highlights Recent Company Progress
- uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
- uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
- Gotham Therapeutics Strengthens Board of Directors and Scientific Advisory Board
- OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter
- uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
- Cellnovo announces its Q4 and Full Year 2018 Sales
- Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test
- Promedior Announces Pivotal Path for PRM-151 in Idiopathic Pulmonary Fibrosis Following Positive End-of-Phase 2 Meeting with FDA
- Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia
- KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms
- uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B
- Forbion Appoints Dr. Carlo Incerti as Operating Partner
- Forbion Leads €40m Series B Financing in Inflazome to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept
- uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day
- uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
- Press Release: Icosabutate latest data shows direct and potent anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells
- uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress
- Forbion Leads €17m Series C Financing of OMEICOS Therapeutics
- Milestone Pharmaceuticals Announces $80 Million Private Financing
- JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
- Data from first in-human clinical trial of SNF472 in haemodialysis patients published in British Journal of Clinical Pharmacology
- New Data Presented at the European Society of Gene and Cell Therapy Annual Meeting Demonstrates up to 40 Times Higher Liver Expression with Optimized Promoter
- uniQure Inc. - uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
- Forbion Co-leads $54m Series A Financing in newly formed Gotham Therapeutics
- Forbion closes oversubscribed fourth life sciences VC fund at EUR 360 million
- uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
- Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1
- Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti- PD-L1 Immunotherapy
- KaNDy Therapeutics successfully raises £25 million in a Series C financing
- uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
- Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board
- Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes
- uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
- Sanifit announces completion of enrollment in CaLIPSO – its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis
- Forbion Portfolio Company Replimune Successfully Completes IPO on NASDAQ
- enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
- Forbion exceeds target with EUR 270 million first close of its fourth life sciences VC fund
- Hookipa Appoints Dr. Christoph Lengauer as a Non-Executive Director
- uniQure Inc. - uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
- Bio-Techne To Acquire Exosome Diagnostics, Inc.
- Dirk Kersten joins Forbion as General Partner
- Cellnovo announces the commercialisation of insulin cartridges following the successful start of large-scale manufacturing at the Flex facility in Althofen, Austria
- uniQure Announces New Appointments to its Board of Directors
- Replimune Appoints Dr. Hyam I. Levitsky To Board Of Directors
- KaNDy Therapeutics announces positive clinical data with lead candidate NT-814 for the treatment of symptoms of the menopause
- Curetis Launches Unyvero System and LRT Cartridge for Lower Respiratory Tract Infections in the U.S.
- Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B
- uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy
- uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
- Curetis Publishes Business and Financial Update for the First Quarter 2018
- uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
- uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
- uniQure Announces Pricing of its Public Offering (2018)
- Curetis Announces Change of the Composition of Its Supervisory Board
- Curetis Publishes Full-Year 2017 Financial Results and Updated Guidance For 2018
- Curetis to Publish its 2017 Annual Results on April 30, 2018
- Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018
- Curetis: Novel Products and Study Data to be Presented at ECCMID 2018
- Allecra Therapeutics to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases
- Forbion participates in £29M Series B Financing of Enterprise Therapeutics to Advance its Ion Channel Modulators for the treatment of Cystic-fibrosis, COPD and severe asthma
- Curetis Establishes U.S. Scientific Advisory Board
- Curetis Receives U.S. FDA De Novo Clearance of Unyvero System and Unyvero LRT Lower Respiratory Tract Infection Cartridge
- Curetis’ Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority
- Allecra Therapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
- Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to Treat Complicated Urinary Tract Infections (cUTI)
- Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018
- Forbion’s Portfolio Company, Prexton Therapeutics Acquired by Lundbeck for up to EUR 905 million (USD 1.1 billion)
- Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology
- Forbion leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases
- AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
- Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis
- Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley
- Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic in Resistant Infections
- Curetis Group: Ares Genetics Receives Funding Commitment For EUR 1.6 Mio. Project; Curetis Announces Non-Audited Financial Results for 2017
- Curetis Unyvero HPN Application Receives Singapore Health Sciences Authority Approval; Updates on Sepsis Host Response Test
- Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology
- Sanifit announces the appointment of Cris Calsada as Chief Financial Officer
- Curetis Expects Near-Term FDA Decision on De Novo Request
- Sanifit Announces Last Patient Last Visit completed in Clinical Trial of SNF472 in Patients with Calciphylaxis
- uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
- uniQure Added to NASDAQ Biotechnology Index
- Forbion leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programme
- Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C Financing
- uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
- Allecra Therapeutics Announces New Staged Financing Deal to Take the Company Through to End of Phase 3
- Curetis Publishes Business and Financial Update for the First Nine Months of 2017
- enGene named Company of the Year by BIOTECanada
- uniQure Announces Pricing of its Public Offering
- Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge
- uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018
- uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family
- Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors
- uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease
- NeRRe Therapeutics appoints Andrew Kay as Chairman of the Board
- KaNDy Therapeutics launched to advance a breakthrough treatment in Women's Health
- MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics
- Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs
- MSD to Acquire Rigontec
- Allecra Announces Initiation of a Phase 2 Clinical Trial for its Novel Antibiotic to Treat Resistant Bacterial Infections
- Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS
- CareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic Tests
- Exosome Launches the MedOncAlyzer™ Pan-Cancer Panel
- Exosome Diagnostics Achieves ISO 13485 Certification
- Milestone Pharmaceuticals Closes $55 Million Series C Financing
- Exosome Diagnostics Completes $30 Million Series C Financing
- Cellnovo 2017 First Half Sales
- Cellnovo concludes a loan agreement for up to €20 million from the European Investment Bank
- Prexton announces initiation of phase II clinical testing in Parkinson’s disease
- argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore)
- Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017
- Cellnovo successfully raises €17.5 million from healthcare investors
- Cellnovo Expands International Distribution Network
- Cellnovo Signs Expanded Agreement to Build Second Production Line with Flex
- Curetis Provides Update on Unyvero LRT FDA 510(k) Submission
- Curetis Provides Business and Financial Update for the First Quarter 2017
- AM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase (recAP) Phase II trial in Acute Kidney Injury
- Forbion announces successful dual listing of portfolio company argenx (ARGX) on NASDAQ
- Curetis to Hold Annual General Shareholders’ Meeting on June 23, 2017
- Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist
- Recent Data on Curetis’ Unyvero ITI Application Demonstrate its Clinical and Health Economic Benefits
- Cellnovo announces its Full Year 2016 Results and Q1 2017 Sales
- American Medical Association (AMA) Grants Exosome Diagnostics a CPT PLA Specific to Its ExoDx® Prostate(IntelliScore) Test
- enGene announces appointment of Theresa Podrebarac, MD, as Chief Medical Officer
- enGene’s mucosal gene delivery platform is successful in targeting PD - L1 expression in the gut, demonstrating effective treatment of colitis and G v HD in preclinical models
- Cellnovo Delivers First Commercial Batch of Insulin Cartridges with Manufacturing Partner, Flex
- Cellnovo announces that Diabeloop is launching a CE marking Registration Study on Artificial Pancreas with Cellnovo pump
- Curetis’ Unyvero Intra-Abdominal Infection (IAI) Cartridge Receives CE Marking
- Cellnovo acquires commercial license for Artificial Pancreas Technology from Type Zero Technologies
- Curetis Expands Supervisory and Medical Advisory Boards
- Monthly information regarding the total number of voting rights and total number of shares of the Company
- Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing
- Curetis to Publish its Annual Results 2016 on April 12, 2017
- Curetis Announces Participation in Major Investor and Scientific Conferences in the Second Quarter 2017
- Cellnovo Announces Arrangement of an Equity Line to Support its Development
- Curetis: Cebit 2017: Computational Biologists Predict Antibiotic Resistances Using Biotech
- uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
- Forbion invests in Prexton Therapeutics’ EUR 29 million (USD 31 million) Series B financing
- Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers
- Cellnovo: 2016 Full-Year Sales
- Sanifit Announces Enrollment of First Patient in CaLIPSO
- Forbion Announces - NeRRe Therapeutics raises £23 million in oversubscribed Series B financing round
- Curetis Files for U.S. FDA Clearance for Unyvero Platform and LRT Application Cartridge
- Pieris Pharmaceuticals to Host Investor Call Today to Discuss Servier Collaboration
- Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co- development Alliance
- Curetis to Present at Key Investor and Scientific Conferences in the First Quarter 2017
- Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections
- ExoDxTM Prostate(IntelliScore): A More Precise, Genetically Informed Prostate Cancer Test
- Mitralign news: Piedmont Hospital Testimonial with Trialign
- Cellnovo update on progress towards full-scale manufacturing of insulin cartridges by Flex
- Positive Phase II in eosinophilic asthma for Pulmagen/Teijin
- Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec
- Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform
- Exosome Diagnostics Announces the First Instrument for Point of Care Liquid Biopsy
- uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients
- Curetis Publishes Business and Financial Update for the First Nine Months 2016
- Cellnovo files for 510(k) approval with the FDA for its mobile, connected, all-in-one diabetes management system
- Rigontec Appoints Dr. Jörg Vollmer as Chief Scientific Officer
- Curetis Announces Positive Top Line Data from U.S. FDA Trial
- Sanifit Announces Initiation of First Clinical Trial of SNF472 in Patients with Calciphylaxis
- Curetis to Present at Several Investor and Scientific Conferences in the Fourth Quarter 2016
- Exosome Diagnostics Enters Agreement with Amgen
- Venturing across the Atlantic
- Cellnovo Strengthens Board by appointing Rémi Soula as a Non-Executive Director
- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its Board of Directors has accepted the resignation of Daniel Soland as chief executive officer (CEO) and an executive member of the Board, effective immediately.
- Forbion’s portfolio company Akarna Therapeutics Ltd acquired by Allergan plc
- Cellnovo raises circa EUR 5.4m in capital increase without preferential subscription rights
- Cellnovo announces its Half Year 2016 Results
- Exosome Diagnostics Announces Launch of ExoDx® Prostate(IntelliScore), a Completely Non-Invasive Liquid Biopsy Test to Help Rule Out High-Grade Prostate Cancer
- Curetis Acquires Patents and Rights to Genetic Antibiotic Resistance and Susceptibility (GEAR) Database and Know-How from Siemens
- First Batch of Cellnovo Insulin Cartridges Produced by Flex
- Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics
- Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge
- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced updated clinical data from its ongoing Phase I/II trial of AMT-060, its proprietary, investigational gene therapy, in patients with severe hemophilia B
- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that updated data from its ongoing Phase I/II clinical study of AMT-060 in hemophilia B patients will be presented at the World Federation of Hemophilia 2016 World Congress
- Curetis Appoints Christopher M. Bernard as Chief Executive Officer of Newly-Formed U.S. Subsidiary
- Curetis Announces Participation in Clinical, Scientific and Investor Meetings in the Third Quarter 2016
- Exosome Diagnostics Enters Partnership with Takeda
- Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections
- Cellnovo: New study highlights superior accuracy of Cellnovo Diabetes Management System compared to other leading patch pumps
- FCF II Co-Invest I supports EUR 22M Series B of Allecra Therapeutics
- Curetis Announces Excellent Study Data and Multi-Region Launch of Unyvero BCU Blood Culture Application Cartridge
- Exosome Diagnostics Appoints John Healy as Vice President of Informatics
- Curetis Publishes First Quarter 2016 Business and Financial Update
- Sanifit Expands Board with Senior Hire
- AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury, and reports completion of first stage in Phase II trial
- Clinical Data for World’s First Truly Non-Invasive Prostate Cancer Test Published in JAMA Oncology
- Forbion closes third life sciences fund, FCF III, raising over $200m
- Curetis Publishes Full-Year 2015 Financial Results and Introduces 2016 Guidance
- Akarna Therapeutics Announces Formation of Clinical Advisory Board
- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
- Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial
- Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update
- Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016
- Cellnovo and Roche Sign Commercial Blood Glucose Monitor Agreement
- Argos Therapeutics Announces Financing of up to $60 Million
- Cellnovo reaches first insulin cartridge industrialisation milestone
- Mitralign Percutaneous Annuloplasty System Earns CE Mark Approval for Functional Mitral Regurgitation
- Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge
- Cellnovo appoints Thierry Moulin as Chief Financial Officer
- Forbion invests in Akarna Therapeutics $15 Million Series B Financing to Develop Novel FXR Agonist-Based Therapies for the Treatment of NASH and other Fibrotic Diseases
- Cellnovo Partners with US Company TypeZero on Artificial Pancreas Programme
- Curetis Expands Commercial Team
- ExoDxTM Prostate(IntelliScore) : A More Precise, Genetically informed Prostate Cancer Test from a Simple Urine Sample
- Exosome Diagnostics Launches World’s First Exosomal RNA - Based Liquid Biopsy, ExoDx™ Lung(ALK)
- Cellnovo: 2015 Full Year sales
- Takeda And enGene Establish Strategic Alliance to Develop Novel Therapeutics
- uniQure Appoints Dan Soland as Chief Executive Officer
- Acerta Pharma Announces Strategic Transaction with AstraZeneca
- Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial
- Cellnovo’s diabetes management system featured in NHS Alliance Programme ‘Communities of Care’
- Engene Inc. Announces the Appointment of Dr. Dennis H. Langer to the Company's Board of Directors
- RSPR Pharma initiates Phase II clinical trial of oral mast cell inhibitor CRD007 in uncontrolled asthma
- Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration
- Appointment of Javaid Masoud as Chief Technology Officer
- Exosome Diagnostics Launches Clinical Commercialization Program for the Research Market
- Exosome Diagnostics’ Exosomal RNA (exoRNA) Plus Cell-Free DNA (cfDNA) Liquid Biopsy Panel
- Curetis IPO priced at EUR 10.00 per Share; raises EUR 40 Million
- Leading Liquid Biopsy Company, Exosome Diagnostics, Appoints John Boyce as Chief Executive Officer
- Cellnovo records strong sales growth over the first 9 months of 2015
- Forbion portfolio company Engene announces collaboration with Johnson and Johnson Innovation
- Curetis and Acumen to Collaborate on Unyvero Sepsis Test and ASEAN Distribution
- Exosome Diagnostics Presents New Data Demonstrating Exosomal RNA-Based Platform’s Ability to Serially and Longitudinally Monitor Response to Immunotherapy Treatment in Patients with Malignant Melanoma
- Curetis Enters into Distribution Agreement to Expand Commercial Activities into Greater China
- Replimune Ltd raises $30 million Series A Financing
- Exosome Diagnostics Announces Publication of ExoIntelliScore™ Prostate Initial Clinical Study Positive Results
- Positive Topline Results Announced from Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure’s Novel AAV5-Based Gene Therapy
- Amgen acquires Forbion portfolio company Dezima Pharma
- Forbion announces the closing of FCF II Co-invest Fund I at EUR 75M
- Exosome Diagnostics Presents Clinical Performance Data for ExoDx™ Lung(ALK) Liquid Biopsy Test and New Data on Detection of EGFR Activating Mutations and T790M Resistance Mutation
- Promedior Announces Initiation of a Phase 2 Clinical Study of PRM-151 in Idiopathic Pulmonary Fibrosis (IPF)
- Forbion invests in Sanifit’s €36.6M ($41M) Series C financing round
- Exosome Diagnostics Announces New Data Demonstrating Superior Ability to Isolate and Extract Highly Pure RNA from Serum and Plasma for Research Applications
- Exosome Diagnostics Raises $17.6 Million in Second Round Series B Financing
- Pieris Pharmaceuticals Strenghtens Senior Management Team and Establishes US Headquarters in Boston
- Mitralign Receives FDA Approval for Percutaneous Tricuspid Repair Early Feasibility Study
- Forbion Announces - Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases
- uniQure Announces Financial Results for Second Quarter 2015
- Forbion Announces Two Successful Initial Public Offerings of Portfolio Companies Pieris Pharmaceutical, Inc and Cellnovo Group SA
- Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock
- Cellnovo: Full exercise of the overallotment option
- Rigontec GmbH Appoints Donald J. deBethizy as Chairman of the Board
- Success of Cellnovo’s IPO with €31.6 million raised on Euronext in Paris
- Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics
- Curetis Initiates Next Phase of Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections
- Pieris Pharmaceuticals Closes Public Offering of Common Stock
- Pieris Pharmaceuticals Prices Public Offering of Common Stock
- Cellnovo launches its IPO on the Euronext regulated market in Paris
- Curetis’ Unyvero System Selected for Global Phase III Antibiotics Trial
- Cellnovo Starts the Expansion of its Distribution Network
- Promedior Presents Additional Positive Phase 2 Data for PRM-151 in Myelofibrosis at EHA Annual Meeting
- Dezima Pharma’s CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet
- Exosome Diagnostics Presents Data on Plasma-Based Solid Tumor Mutation Panel Liquid Biopsy Test
- Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference
- Exosome Diagnostics Announces Positive Results from Large Clinical Validation Study of Prostate Cancer Liquid Biopsy
- Forbion invests in Autonomic Technologies Europe GmbH
- Forbion Announces that Pfizer Acquires Minority Interest in its Portfolio Company AM-Pharma; Secures Option to Acquire Company
- Curetis Strengthens Executive Team; Appoints Dr. Achim Plum as Chief Commercial Officer
- Exosome Diagnostics Presents Data Demonstrating Ability to Detect EML4-ALK Fusion Transcripts on Exosomal RNA in Patients with Non-Small Cell Lung Cancer
- Curetis Expands Commercial Organization
- Curetis to Launch Next-Generation Pneumonia Application at ECCMID 2015
- Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases
- Forbion Capital Partners Invests EUR 2.4 Million in 2nd Closing of Series A Financing Round for Rigontec GmbH
- Curetis Initiates Clinical CE Performance Evaluation of Unyvero P55 Pneumonia Application
- Cellnovo announces the registration of its document de base in the context of its planned IPO on the regulated market of Euronext in Paris
- Exosome Diagnostics Announces Positive Results from Initial Clinical Study of Novel Prostate Cancer Liquid Biopsy
- Forbion Capital Partners leads CAD 13.5 Million (EUR 9.6 million) Series B financing round for enGene Inc.
- AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury
- arGEN-X Launches Innovative Access Program
- Exosome Diagnostics and the Addario Lung Cancer Medical Institute (ALCMI) Announce Collaboration to Accelerate Development of Plasma-Based Lung Cancer Diagnostics
- Forbion Portfolio Company Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million
- Pieris Initiates Phase I Clinical Trial for Anticalin® to Treat Anemia
- arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire
- Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting
- Pieris Achieves GLP Tox Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics
- Forbion Announces Sale of Portfolio Company PneumRx to BTG for up to USD 475M (EUR 385M)
- Preclinical data published on AM-Pharma’s recAP to treat ultra rare disease Hypophosphatasia
- Pieris Achieves Second Preclinical Milestone Payment in Sanofi Collaboration
- Curetis Closes EUR 14.5 Million Extension to Series B Financing
- Exosome Diagnostics Demonstrates Superior Mutation Detection Utilizing Combined Exosomal RNA (exoRNA) and Cell-‐Free DNA (cfDNA) Isolation and Analysis
- arGEN-X – Third Quarter Business Update
- AM-Pharma presents preclinical data on mode-of-action for recAP in Acute Kidney Injury at ASN meeting
- Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study
- Pieris Appoints Michael Richman as Supervisory Board Member
- arGEN-X Initiates Clinical Efficacy Evaluation of ARGX-110 in Patients with Relapsed/Refractory CD70-Positive T-Cell Lymphomas
- Invetech and Argos Therapeutics Announce Agreement to Support Global Production
- Argos Therapeutics Breaks Ground on State-of-the-Art Biomanufacturing Facility
- Promedior Receives Fast Track Designation for PRM-151 for the Treatment of Myelofibrosis
- arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia
- arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110
- Mitralign Confirms First-In-Man Percutaneous Tricuspid Repair
- Forbion Capital Partners Announces First Close of FCF III
- Curetis Presents New Unyvero Pneumonia Data at Major Clinical Microbiology Meetings
- Promedior Announces Presentation of Retrospective Quantitative Imaging Analysis of Phase 1b Data in Idiopathic Pulmonary Fibrosis
- arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-positive Solid Tumors into its Phase 1b expansion trial with ARGX-110
- Enrollment in Argos Therapeutics' Pivotal Phase III ADAPT Trial of AGS-003 for Metastatic Renal Cell Carcinoma Surpasses Fifty Percent
- arGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive accelerated grant in the United States
- Pulmologix Raises €9.6 Million to Develop a New Oral Non-Steroidal Anti-Asthmatic Drug
- AM-Pharma closes €12.2m financing round
- uniQure Announces Results for the Second Quarter and First Half of 2014 and Provides Update on Gene Therapy Programs
- Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia
- arGEN-X announces positive preclinical results for ARGX-113
- Skyepharma acquires a novel inhaled therapy platform
- uniQure Acquires Cardiology Gene Therapy Company InoCard
- Chiesi and uniQure Provide Update on Glybera® Launch
- Forbion Announces Sale of Portfolio Company, Santaris Pharma, to Roche for up to $450m
- Exosome Diagnostics Announces Appointment of Thomas McLain as Chief Executive Officer
- Xention awarded £1.4m from Technology Strategy Board to Develop New Medicines for Atrial Fibrillation
- bluebird bio Announces Pricing of Public Offering of Common Stock
- Dezima Pharma Extends Clinical Development Program for its CETP Inhibitor TA-8995
- Forbion Announces Closing of Initial Public Offering of Portfolio Company arGEN-X
- uniQure Secures Additional $10M Venture Loan from Hercules Capital
- Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics
- uniQure Announces Will Lewis as New Board Member
- arGEN-X and The Leukemia & Lymphoma Society Partner on the Development of ARGX-110 for the Treatment of Waldenström’s Macroglobulinemia
- arGEN-X enters long-term Strategic Alliance with Shire Pharmaceuticals in Therapeutic Antibodies
- Treatment With AGS-003 and Sunitinib Associated With Doubling of Expected Survival in Patients With Unfavorable Risk Metastatic Renal Cell Carcinoma (mRCC)
- uniQure and Medison Sign Glybera® Distribution Agreement for Israel
- Promedior to Present Positive Preliminary Phase 2 Data for PRM-151 in Myelofibrosis at ASCO Annual Meeting
- arGEN-X to Present Results of Phase 1 Study of ARGX-110 in Patients with Advanced Cancer at ASCO
- Forbion Advisor awarded prestigious Anitschkow price
- arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates
- Argos Therapeutics Named as a Red Herring Top 100 North America Winner
- uniQure Announces Successful Transfection of Liver Cells with AAV5 and Strong Safety Data from Acute Intermittent Porphyria Clinical Trial
- Ario Pharma Strengthens Scientific Advisory Board with Two Key Appointments
- Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at ASCO
- Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyvero LRT Trial
- Curetis Launches Unyvero i60 Implant and Tissue Infection Cartridge in Europe
- New Favorable Clinical Evaluation Data for Unyvero P50 Pneumonia Application
- arGEN-X Appoints Dr Werner Lanthaler to its Supervisory Board
- uniQure Announces Changes in Management Team
- arGEN-X Uses its Simple Antibody™ Platform to Identify Four "Hotspots"
- Forbion's portfolio company Hookipa Biotech winner of the Best Financing Deal Award in the Vaccine Industry Excellence Awards 2014
- AM-Pharma announces positive Phase I data on recAP for Acute Kidney Injury
- Exosome Diagnostics Raises $27 Million in Series B Financing
- Amakem Appoints Dr. James Tsai of the Yale School of Medicine to its Clinical Advisory Board
- Curetis Prepares Launch of Second Unyvero Application
- Acquiring orphans Rogier Rooswinkel, Geert-Jan Mulder & Sander van Deventer
- Forbion Announces Closing of Public Offering of Portfolio Company, Argos Therapeutics
- Forbion Announces Closing of Initial Public Offering of Portfolio Company uniQure
- Pieris Achieves Preclinical Milestone Payment in Sanofi Collaboration
- Dezima Pharma Completes Patient Enrolment for TULIP Phase 2b Study with CETP Inhibitor TA-8995
- Exosome Diagnostics and QIAGEN Expand Collaboration to Develop Non-Invasive Biofluid Diagnostic for Lung Cancer
- arGEN-X starts Phase Ib expansion cohorts with ARGX-110, a Novel anti-CD70 Antibody, in Cancer Patients
- arGEN-X Receives Two Preclinical Milestone Payments under Collaboration with Shire
- Pieris Achieves Fourth Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics
- Curetis and Laboratorios LETI Sign Exclusive Distribution Agreement for UnyveroTM in Spain and Portugal
- Promedior Attains Patient Enrollment Milestone in Phase 2 Clinical Study of PRM‐151 in Myelofibrosis
- Promedior Appoints William Hodder as Vice President of Business Development
- Stelis Biopharma and Pieris Forge Alliance for Novel Anticalin® Therapeutics in Ophthalmology
- ARGX-110 meets translational development goals in dose escalation part of Phase Ib cancer study
- Clinical Trial Launched to Treat Sanfilippo B Syndrome Using Gene Therapy
- Argos Therapeutics Announces Additional $17.5 Million of Series E Financing Bringing Total Commitment to $60 million
- Amakem Presents Positive Top-Line Clinical Results for AMA0076 for Glaucoma at Ophthalmology Innovation Summit
- Pieris Receives Third Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics
- Argos Therapeutics Presents Data Showing Memory T Cell Expansion
- AM-Pharma presents positive data from recAP preclinical study at ASN meeting
- Hookipa Biotech Closes €20 Million ($27.5 Million) in Series B Financing
- arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer
- arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B
- Curetis Receives Clearance for Unyvero System and Pneumonia Application in Russia and Serbia
- PneumRx, Inc.'s RePneu Coil Becoming Therapy of Choice for Patients with Severe Emphysema
- Curetis Presents First Data on Novel Unyvero i60 ITI Application for Implant and Tissue Infections
- Zydus and Pieris Sign Broad Co-Development Alliance for Novel Anticalin® Therapeutics
- Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis
- Curetis Presents New Clinical Validation Data on its Unyvero™ P50 Pneumonia / LRT Application
- Christian Meyer Joins uniQure as Chief Medical Officer
- uniQure Selected as Fierce 15 Company by FierceBiotech
- Xention and Servier announce a cardiovascular collaboration to further develop modulator for the treatment of atrial fibrillation
- Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
- arGEN-X Reaches Milestone in Simple Antibody™ Research and Product Development Collaboration with Shire
- arGEN-X initiates Phase IB study of ARGX-111 in cancer
- JAIDS Study by Argos Therapeutics Evaluates Impact of Personalized Immunotherapy in HIV-Infected Patients
- arGEN-X Identifies Potent Antibody Antagonist Against Complex Chronic Pain
- Santaris Pharma A/S Completes Enrollment in Phase 2 Clinical Trial of Miravirsen
- Shire and Santaris Extend their Strategic Alliance to Discover and Develop LNA-drugs in the Rare genetic disease field
- Argos Therapeutics Secures $42.5 Million Financing, Funds Pivotal Phase 3 ADAPT Trial for Personalized Immunotherapy
- Mount Sinai and Exosome Diagnostics Partner to Accelerate Translation of Body Fluid Molecular Diagnostics to Overcome Limitations of Tissue Biopsy in Areas of Critical Unmet Medical Needs
- gIcare Pharma initiates Phase 2a study of its lead product, GIC-1001, in sedation-free analgesia for colorectal cancer screening
- uniQure to build 55,000 square foot state-of-the-art gene therapy production plant in US to leverage AAV-manufacturing strength
- Exosome Diagnostics and QIAGEN Partner to Launch Comprehensive Line of Biofluid Nucleic Acid Kits to Address Limitations of Tissue Biopsy in Clinical Research Market
- uniQure signs EU commercialization agreement with Chiesi Farmaceutici
- Curetis Initiates Prospective Multicenter Unyvero Study in Europe
- Exosome Diagnostics Names Joseph Slattery to the Board of Directors
- Argos Therapeutics Announces Plans for HIV Eradication Study
- bluebird bio Announces Pricing of Initial Public Offering
- Leading HIV Researchers and Argos Therapeutics Highlight Importance of Immunotherapy in HIV Eradication Efforts
- Dezima Pharma Appoints Seasoned New CEO
- Argos Therapeutics Announces US and Global Expansion for Ongoing Pivotal Phase 3 ADAPT Study for Personalized Immunotherapy
- uniQure and consortium to receive EUR 2.5 million Eurostars grant to develop RNAi gene therapy for Huntington’s disease
- CircuLite® Receives Approval to Begin CE Mark Trial for SYNERGY® IC Circulatory Support System
- Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prostate Biopsy Outcome at American Urological Association Annual Meeting
- Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
- bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.
- Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors
- arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders
- Curetis raises EUR 12.5 million in Series B round
- Forbion Capital Partners co-leads €15 Million Series A Financing for Allecra Therapeutics
- Santaris Pharma announces a worldwide discovery alliance with BristolMyers Squibb for RNA-targeted medicines
- Exosome Diagnostics Presents Data at the International Society for Extracellular Vesicles 2013 Annual Meeting
- Pieris and Sanofi Broaden Existing Collaboration
- Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
- arGEN-X announces preclinical development of ARGX-112 for dermatology
- bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology
- Argos Therapeutics Welcomes Jean Lamarre to Board of Directors
- Curetis AG Strengthens Commercial Team and Expands Distribution Network
- CircuLite® Receives Conditional IDE Approval for SYNERGY® Circulatory Support System feasibility Trial
- Dezima Pharma raises €14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001
- uniQure Named to MIT Technology Review’s 2013 50 Disruptive Companies List Recognizing World’s Most Innovative Companies
- Argos Therapeutics Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metastatic Renal Cell Carcinoma
- Argos Therapeutics to Present on Automated Manufacturing Process at 2013 Cell and Gene Therapy Forum
- uniQure Appoints Philip Astley-Sparke President US
- Dezima Pharma in-licenses CETP Inhibitor Program from Mitsubishi Tanabe Pharma Corporation
- Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study
- arGEN-X Expands its Therapeutic Antibody Alliance with Shire
- arGEN-X Initiaties Phase Ib Study of ARGX-110 in Cancer
- Promedior Opens New Office and Laboratories in Lexington, Mass.
- uniQure licenses RNA interference technology to advance Huntington’s disease program
- uniQure initiates Phase I in acute intermittent porphyria
- uniQure Appoints Hans Christian Rohde Chief Commercial Officer
- arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform
- Curetis and Scholz Collaborate to Industrialize and ScaleUp Production of Unyvero Cartridge Plastics Parts
- Pieris Presents Data and Reveals Targets for Anticalin® Bispecific PRS-190 at European Antibody Congress
- Study shows innovative ERT-based solution has the potential to address unmet clinical needs across a range of lysosomal storage diseases
- Forbion Announces Appointment of Two Leading Experts in Oncology and Metabolic Disease as Scientific Advisors to its Various Funds
- Argos Therapeutics Study Confirms Optimal Quality Control Methods for Production of its RNA-Based Immunotherapies
- Insmed Announces CLEAR-108 Phase 3 Clinical Study Has Completed Target Enrollment
- Insmed Appoints Andrew Drechsler as Chief Financial Officer
- Southeast BIO Recognizes Argos Therapeutics with the "2012 Southeast BIO Deal of the Year
- Forbion Portfolio Company uniQure receives Approval for Glybera® First Gene Therapy by European Commission
- Exosome Diagnostics Selects Promega Corp. for cGMP Clinical Sample Concentrator Kit
- ARGEN-X appoints Dr. David L. Lacey to its Supervisory Board
- Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer
- Promedior Expands Series D Round of Financing
- Eric Rose, M.D., named Chairman of the CircuLite Board of Directors
- Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics
- Curetis Completes Enrollment for its EU Trial
- RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody
- Amakem Initiates Phase 2a Proof of Concept Study with the Rho Kinase (ROCK) Inhibitor AMA0076 in Patients with Glaucoma and Ocular Hypertension under a US IND
- Teijin Pharma and Pulmagen Therapeutics Sign Exclusive Agreement
- 21st Century Health and Business highlighted novoGI
- Curetis AG to Present Its Unyvero™ Solution at DGHM Conference
- Insmed Appoints Will Lewis as President and Chief Executive Officer
- Forbion Announces Appointment of Philip Astley-Sparke as Venture Partner
- Forbion Portfolio Company Circulite® Receives CE Marking Approval For SYNERGY® Circulatory Support System
- bluebird bio Secures $60 Million in Oversubscribed Financing
- Forbion portfolio company, uniQure receives positive opinion for Glybera® in Europe from CHMP
- Curetis AG Signs Distribution Deal in Middle East with ATC
- Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial
- uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson’s Disease
- novoGI™ Announces Purchase of IP and Collaboration with Leading Gastroenterologist Dr. Christopher Paul Swain
- Cytheris appoints Damian Marron as chief executive officer
- Argos Therapeutics Presents Positive Phase 1a Data for AGS-009 in Patients with Lupus at 2012 EULAR Congress
- Exosome Diagnostics Signs Agreement with Life Technologies to Use Real-Time PCR Platform for Exosome Biofluid In Vitro Oncology Diagnostics
- INSMED PROVIDES CORPORATE UPDATE | Company Sets Current ARIKACE® Development Priorities | Insmed Projects Cash Sufficient to Generate Top-Line Data from Three Priority Studies
- PneumRx, Inc. Acquires Key Broncus Assets
- PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System
- Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
- Promedior Appoints Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer
- arGEN-X Granted first US patent covering its unique NHance technology
- Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
- Pieris presents preclinical Data for PRS-110 at AACR Annual Meeting
- Kapil Dhingra, Former Head of Roche Oncology, Joins Exosome Diagnostics Board of Directors
- arGEN-X Appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel
- arGEN-X Launches NHance™ Technology to Generate Better Human Antibody Therapies
- Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
- Promedior Receives U.S. Orphan Drug Designation for PRM‐151 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin‐2 Therapeutics for Fibrotic Diseases
- arGEN-X enters into a therapeutic antibody alliance with Shire
- Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV
- Curetis AG Initiates Prospective Clinical Trial for Rapid Pneumonia Diagnostics
- Cellnovo launches world's first mobile-connected diabetes management system with largest ever usability trial of insulin pump technology
- arGEN-X advances a third therapeutic antibody program into preclinical development
- Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
- Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin® Program
- Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)
- Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
- EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
- AM-Pharma Announces Appointment of Russell Greig as Chairman
- arGEN-X is awarded €1.3 million IWT Grant to Advance Proprietary SIMPLE Antibody™ Platform for Addressing Challenging Disease Targets
- Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin® Program at ASH Annual Meeting
- Forbion Announces Closing of Second FCF 1 Co-Investment Fund
- Cellnovo's Mobile Health Approach to Diabetes Care
- Forbion portfolio company CircuLite, Inc raises $30m in Series D round
- Forbion portfolio company Argen-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B round
- Oxyrane Raises $26.5m in Series D Financing
- Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
- Forbion Capital Partners leads € 9.6 Million Expansion Financing of Curetis AG
- Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin® Pipeline Development
- Forbion Capital Partners and Sofinnova participate in the €7 million Series A Financing of Hookipa Biotech
- The Prostate Cancer Foundation and Exosome Diagnostics Collaborate to Accelerate Clinical Validation of Exosome Biofluid Molecular Diagnostics in Prostate Cancer
- Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology
- Cardoz announces the successful completion of enrollment in the AORTA trial investigating CRD007 in patients with Abdominal Aortic Aneurysm
- Cellnovo Receives 2011 European Technology Innovation Award in Diabetes Care
- Argos Therapeutics’ Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
- AM-Pharma Raises €29.2m in Series D Financing
- Forbion announces acquisition of Pathway Medical Technologies by Bayer Healthcare
- Forbion Capital Partners leads €18 Million Financing of Amakem NV
- Forbion Capital Partners leads CAD$7 Million Series A financing of gIcare Pharma, Inc.
- Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
- Cardoz announces the start of the international phase II dose-finding AORTA trial investigating a new oral drug treatment for Abdominal Aortic Aneurysm
- Argos Therapeutics’ Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination with Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
- Exosome Diagnostics Announces Expansion of Scientific Advisory Board
- Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin® PRS-080 Hepcidin Antagonist Drug Program
- Promedior Presents Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2011
- Santaris Pharma A/S advances a second drug from its cardiometabolic program, SPC4955, inhibiting apoB, into Phase 1 clinical trials for the treatment of high cholesterol
- Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011
- BioGeneration Announces Closing of BioGeneration Ventures II
- Promedior Announces Presentation of Data at ARVO Demonstrating that PRM-151 (rhPTX-2) Suppresses Choroidal and Retinal Neovascularization
- bluebird bio Secures Additional $30 Million in Financing
- Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin® Therapeutics
- Provesica Starts Phase 2 Study in Overactive Bladder
- Pieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine Tri-Conference
- IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology
- IL-7 Knocks the Socs Off Chronic Viral Infection
- Cytheris Announces Publication of Preclinical Study in Cell Showing That Interleukin-7 Engages Multiple Mechanisms To Overcome Chronic Viral Infection and Limit Organ Pathology
- Xention and Grünenthal enter Drug Discovery Collaboration in Ion Channel Research
- Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Pulmonary Fibrosis
- Promedior Initiates Clinical Study of Anti-Fibrotic Therapeutic, PRM-151, in Patients with Idiopathic Pulmonary Fibrosis (IPF)
- Cellnovo to Secure £30 Million in Series B Financing
- Key Genes Associated with Cancer Found in Circulating Blood Microvesicles
- AMT Receives € 1.1 Million Funding for Acute Intermittent Porphyria Gene Therapy as part of EU Consortium Grant
- Forbion announces Amgen agreement to acquire portfolio company Biovex for up to US$1 billion
- AMT to Supply cGMP Manufacturing to Consortium Led by Institut Pasteur for Clinical Development of Gene Therapy for Rare Genetic Disorder in Children
- Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration
- Forbion Capital Partners leads $33 Million Series C financing of PneumRx, Inc.
- arGEN-X signs discovery and development alliance with Lilly
- Santaris Pharma A/S announces expanded worldwide strategic alliance with Pfizer Inc. directed to development of RNA-targeted medicines
- Argos Therapeutics Initiates Dosing of Patients in Phase 1 Clinical Trial of Monoclonal Antibody-Based Therapy for Treatment of Systemic Lupus Erythematosus
- £4m Financing into Provesica to Complete Phase 2 Trial for Overactive Bladder
- Xention Spins Out Overactive Bladder Business
- Forbion Capital Partners announces that INSMED INCORPORATED and TRANSAVE, INC. combine their businesses
- Argos Therapeutics Initiates Dosing of Patients in Phase 2b Clinical Trial of Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients
- Cytheris Announces Publication of Clinical Case Study Combining Recombinant Human Interleukin-7 (CYT107) with Antiviral Agent CMX001 as Potential Treatment for Progressive Multifocal Leukoencephalopathy (PML)
- AMT Submits Responses to Day 120 Questions to EMA as part of the review process for Glybera®
- Xention Raises £8 Million in Private Equity Placement
- Argos Therapeutics’ Arcelis™ Immunotherapy for Renal Cell Carcinoma Demonstrates Encouraging Results in Phase 2 Combination Study with Sunitinib
- Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo with Enhanced Novel MicroRNA AAV Gene Therapy
- ARIKACE™ demonstrates sustained benefit in multiple studies and over multiple cycles of treatment of pseudomonas lung infections in cystic fibrosis patients
- Amsterdam Molecular Therapeutics Successfully Raised €14.3m Through an Equity Issue
- Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics
- arGEN-X awarded €1.5 million IWT grant to accelerate pre-clinical antibody development
- AMT receives orphan drug designation from the U.S. Food and Drug Administration Duchenne Muscular Dystrophy gene therapy
- Cardoz Raises SEK 124 M ($ 17 M, € 13 M) in Series A Financing to Develop Drug for Aortic Aneurysm
- NATURE Publishes Promising Results on Treatment of First Patient in bluebird bio’s Phase 1/2 Beta-Thalassemia Study
- Promedior Announces Initiation of Phase 2a Clinical Study of Anti-Fibrotic Therapeutic, PRM-151, in the Prevention of Post-Surgical Scarring in Glaucoma Patients
- Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Asthma and Asthma-Induced Lung Fibrosis
- Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer
- Forbion Capital Partners raises €190m for new investments
- AMT’s Marketing Authorisation Application for Glybera® Progressing On Schedule
- Argos Therapeutics’ Arcelis™ HIV Immunotherapy Demonstrates Significant Reduction in Viral Load and Delay in Viral Rebound Kinetics in Interim Analysis of Phase 2 Study
- arGEN-X granted broad patent covering its unique simple antibody™ platform
- Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
- Pieris AG Appoints Chief Scientific Officer
- Cytheris Closes €12 Million ($15 Million) Series D Financing
- Amsterdam Molecular Therapeutics Reports Promising Data from Cholesterol Lowering Gene Therapy Study
- Forbion Capital Partners co-leads $20 Million Series A Financing of Exosome Diagnostics
- Forbion Capital Partners Leads €10M Series A Financing in Cardoz to Develop Drug for Aortic Aneuryism
- Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
- Argos Therapeutics Presents Transplantation Data for Soluble CD83 Demonstrating its Ability to Induce Immune Tolerance and Suppress Anti-donor Antibody Responses
- Argos Therapeutics Publishes Positive Immune Response, Safety and Manufacturing Data for its Arcelis™ HIV Program in Clinical Immunology
- Argos Therapeutics Presents Positive Phase 2 Data of its Arcelis™ Personalized Immunotherapy Platform in Metastatic RCC at ASCO GU Symposium
- Forbion Capital Partners Opens German Office and Expands Team
- Forbion Capital Partners leads $12 Million Series C Financing of Promedior Inc.
- Genetix Pharmaceuticals secures $35M in Series B Funding
- arGEN-X SIMPLE ANTIBODY™ PLATFORM SET TO TRANSFORM THERAPEUTIC ANTIBODY DISCOVERY & DEVELOPMENT
- Amsterdam Molecular Therapeutics Amends Amgen GDNF Gene License Agreement
- AMT initiates Phase I/II Gene Therapy Clinical Trial for Hemophilia B
- Genetix Pharmaceuticals appoints Mitchell Finer, Ph.D. as Chief Scientific Officer
- Galapagos acquires Argenta Discovery's service operations
- EMA starts formal review of Glybera® dossier
- AMT submits its lead product Glybera Application for Marketing Authorisation Application to EMA
- Pieris appoints a new CEO
- Amsterdam Molecular Therapeutics (AMT) successfully raises EUR 5 million via a Convertible Bond issue with shareholder Forbion
- arGEN-X concludes EUR 12.5 million Series A financing round
- PanGenetics announces acquisition by Abbott of PG110 anti-NGF antibody to treat chronic pain
- Genetix Pharmaceuticals Announces Global Clinical Plans to Treat Adrenoleukodystrophy (ALD)
- AMT Successful in Preclinical Treatment of Duchenne Muscular Dystrophy
- BIOVEX ANNOUNCES PUBLICATION OF PHASE 2 MELANOMA RESULTS WITH ONCOVEX GM-CSF IN THE JOURNAL OF CLINICAL ONCOLOGY
- AMT Starts Development LPLChipTM with Progenika
- TRANSAVE COMPLETES SUCCESSFUL PHASE II CLINICAL PROGRAM FOR ARIKACE IN THE TREATMENT OF PSEUDOMONAS LUNG INFECTIONS
- Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis™ HIV Program at the AIDS Vaccine 2009 Conference
- AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy
- Pieris reports preclinical development progress of its next generation VEGF antagonist
- Sanofi-aventis to acquire FOVEA Pharmaceuticals, a French biopharmaceutical ophthalmology company
- Joern Aldag appointed as AMT's CEO
- Cytheris Announces Interim Data From INSPIRE Study Showing Interleukin-7 (CYT107) Induces Dose-Dependent and Sustained Increase of CD4 T Cells in Chronic HIV Infected Patients
- Pieris AG enters into Anticalin Collaboration with Allergan, Inc.
- Transave announces positive phase II results for once-daily Arikace™ in the treatment of non-cf bronchiectasis patients who have pseudomonas lung infections
- Forbion Capital Partners co-leads EUR 9.5 million financing of arGEN-X B.V.
- Forbion Capital Partners leads $18.5 million financing of NiTi Surgical Solutions
- Synergy®, Circulite's Micro-blood pump, shown to provide sustained improvements in cardiac function and evidence of myocardial recovery in patients with chronic heart failure
- PanGenetics Receives Approval for Clinical Evaluation of Anti-NGF Antibody in Patients with Chronic Pain
- Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
- Argenta Discovery Announces Entry into Phase I for First Candidate from Collaboration with AstraZeneca to Develop Improved Inhaled Bronchodilators for COPD
- Argenta Discovery and Porsolt Join Forces to Provide Fully-integrated CNS and Pain Contract Drug Discovery Services
- AMT Starts Preregistration Trial for Glybera
- Fovea Reports Positive Results with PrednisporinTM in Persistent Allergic Conjunctivitis
- TRANSAVE COMPLETES ENROLLMENT IN ARIKACETM PHASE II BRONCHIECTASIS STUDY
- BIOVEX COMMENCES ONCOVEX GM-CSF PIVOTAL TRIAL IN MELANOMA
- CIRCULITE DEMONSTRATES LONG-TERM IMPROVEMENTS AND HEMODYNAMIC BENEFITS WITH SYNERGY® PARTIAL CIRCULATORY SUPPORT IN CHRONIC HEART FAILURE PATIENTS
- CIRCULITE® COMPLETES INITIAL CLOSE ON $33 MILLION SERIES C FINANCING PLAN AND APPOINTS CHIEF MEDICAL OFFICER
- Xention Enters Drug Discovery Agreement with Ono Pharmaceutical Co., Ltd.
- Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
- DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6® Cell Line Proteins
- Pieris reports development progress for Anticalin® PRS-050, a next generation VEGF antagonist
- AMT CEO Ronald Lorijn Steps Down - Sander van Deventer Interim CEO
- Mitralign Initiates it's First European Study
- Argos Therapeutics Completes $35.2 Million Series C Financing
- AMT intends to incorporate additional data to its Marketing Authorization Dossier for Glybera
- AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform
- Pathway Medical Technologies Receives FDA Clearance for Jetstream Pathway PV Atherectomy System
- AMT prepares for submission of Marketing Authorization Dossier for AMT-011 (Glybera?)
- AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
- Biovex reports positive phase II clinical trial results of Oncovex GM-CSF in metastatic melanoma at the 2008 American Society of Clinical Oncology meeting
- AMT's Cooperative Research and Development Agreement with NIH to Boost Production Capacity
- AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
- Pathway Medical Technologies, Inc. Secures $24.5 Million Financing
- Argos Therapeutics Secures $35.2 Million Series C Financing
- Forbion’s Portfolio Company Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
- Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis™ Platform in HIV at Keystone Symposia
- Forbion’s Portfolio Company Pieris AG raises € 25 M (US$ 38M) in Series B financing round
- Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
- CircuLite announces initiation of European registration study for Synergy™ Circulatory Assist Device
- Forbion Capital Partners co-invests in 23M EURO series C financing of PanGenetics
- Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022
- Circulite reports preliminary results of first-in-man pilot study for Synergy circulatory assist device
- Cytheris Announces 48-Week Results of Phase I/II Study Showing Administration of Interleukin-7 (IL-77) Significantly Improves CD4 T-Cell Counts in Chronically Infected HIV-1 Patients
- Mitralign Successfully Completes First Human Case
- Argos Therapeutics Publishes Novel Approach to Amplifying HIV Genes for Personalized Immunotherapy Treatments for HIV
- Forbion Capital Partners co-leads $24m Series C Financing of Mitralign
- AMT’s Lead Product Poised to Address Major Liver Disease: European Patent Office Grants Patent for Treatment of Non-alcoholic Steatotic Hepatitis
- Mitralign Announces the Closing of a Series C Financing
- Cytheris Releases Promising Clinical Data on it's Interleukin-7 Immune Enhancer at the 2007 CROI Meeting in Los Angeles
- Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 with trial fully recruited and European and US Submission On Track for first half of 2008
- FlowMedica Announces Completion of the Benephit System Renal Infusion Therapy (Be-RITe) Registry
- Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, And Moves to Larger Facility to Accommodate Rapid Growth
- Amgen to Acquire Alaska Pharmaceuticals
- Revolutionary Miniature Blood pump from Circulite successfully implanted in first chronic heart failure
- Biovex Raises $22 Million in First Close of Series E Financing
- Bram Bout Joins Bioceros as CEO
- Amsterdam Molecular Therapeutics announces pricing of Initial Public Offering
- Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin technology
- Amsterdam Molecular Therapeutics announces launch of Initial Public Offering (IPO) on Euronext Amsterdam
- Forbion Announces Successful Exit from Alantos Pharmaceuticals
- AMT Presents Positive Results of Phase I/II Study with Lead Product at Annual Meeting of American Society of Gene Therapy
- AMT appoints Ferdinand Verdonck as Chairman of the Supervisory Board
- Amsterdam Molecular Therapeutics announces intention to launch an Initial Public Offering (IPO) on Euronext Amsterdam
- Pieris AG, a biopharmaceutical company developing Anticalins, a novel class of targeted human protein therapeutics
- Forbion Capital Partners adds top tier investors to its investor base
- CircuLite™ Closes an Additional $5M in Series B Private Placement Funding
- Argos Therapeutics Awarded U.S. Patent for CD83 Protein for Use in Immunological Disorders
- Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin® in preclinical studies
- ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
- CircuLite™ Closes $20M Series B Private Placement Funding
- Argos Therapeutics Initiates Personalized Immunotherapy Clinical Trial in HIV Patients
- Amsterdam Molecular Therapeutics BV receives global rights to develop and commercialize AMT-020 for ...
- Forbion Partner Sander van Deventer receives award for development of new therapies for Crohn's disease
- AM-Pharma announces the appointment of Bart Wuurman as CEO
- Pangenetics B.V. licenses therapeutic antibody from Schering Plough Corporation
- Jan van Heek joins PanGenetics' Supervisory Board
- B-Cell Chronic Lymphocytic Leukemia Clinical Trial Initiated with Argos Therapeutics’ AGS-005 Personalized Immunotherapy
- Argenta Discovery and AstraZeneca sign a Research Collaboration and Licensing Agreement to Discover Improved Bronchodilators for COPD
- FDA approves Enzon IND for Santaris Pharma's Second New Cancer Drug
- Analysis by AlgoNomics reveals that Anticalins® intrinsically have an immunogenicity level comparable to the wild-type human lipocalin
- Amsterdam Molecular Therapeutics BV (AMT) Acquires License to AAV Patents from Targeted Genetics Corporation
- First closing of BioGeneration Ventures Fund
- Pathway Medical closes $25 million Series B funding raising
- Pieris confirms in vivo activity of potent VEGF-specific Anticalin
- Cytheris closes EUR 24.3M (USD 30.7M) Series B financing Funds to progress Phase II clinical studies of IL-7 to treat HIV
- Alantos pharmaceuticals and servier form collaboration
- Claus Braestrup, CEO of Lundbeck, appointed to Santaris Pharma Board
- SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline
- NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
- Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
- Forbion Co-Leads $372.5 Million Series D Financing in MapLight Therapeutics
- Citryll Announces Formation Of Scientific Advisory Board
- Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease
- AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
- Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis
- Inflazome receives funding from The Michael J. Fox Foundation for Parkinson’s Research
- First Patient Dosed in Citryll's Phase IIA Trial Evaluating CIT-013 i Rheumatoid Arthritis
- Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression
- Forbion Impact & ESG Report 2024
- Forbion Co-Leads $45M Series A in Genomines
- VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement
- Forbion Co-Leads $95m Series B in Sparrow Pharmaceuticals
- Forbion Portfolio Company Orbis Medicines Named in 2025 Endpoints 11
- CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC
- Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia
- Jon Edwards, PhD, Appointed Partner
- AM-Pharma completes enrollment in Phase 2 study of ilofotase alfa for prevention of cardiac surgery-associated renal damage
- MapLight Therapeutics Announces Commencement of Initial Public Offering
- Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
- Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD
- Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress
- Forbion Promotes Mathias Vinther, PhD to Partner within its Growth Strategy
- Forbion Co-Leads $70 Million Series A Financing for Elevara Medicines to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline
- Plattform Life Sciences interview
- Europe’s biotech and healthcare future depends on more capital, faster access, and smarter incentives
- MapLight Therapeutics Announces Pricing of Initial Public Offering
- Forbion Co-Leads $20M Series A in PACT to Scale Revolutionary Biomaterials
- Forbion Co-leads $141 Million Series B of AAVantgarde Bio to Accelerate Gene Therapies for Stargardt Disease and Usher 1B Syndrome
- Forbion Appoints Joy Faucher as General Partner to Support Continued Growth in Its BioEconomy Strategy
- Forbion closes oversubscribed BioEconomy Fund I at €200 Million Hard Cap
- Braveheart Bio Launches with $185M Series A Aiming to Transform Care of Hypertrophic Cardiomyopathy
- Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause
- Forbion Leads $65 Million Series B Financing in Gate Bioscience to Advance First-in-Class Oral Molecular Gate Medicines into the Clinic
- Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)
- Financial Investigator - Strategic Autonomy Begins with a Strong Home Market
- Fierce Biotech - Jefferies' London conference cements reputation as 'JP Morgan for Europe'
- Financial Times - The looming ‘patent cliff’ facing Big Pharma
- Financial Times - Europe’s plan to finally make its single market work
- Financial Times - Rapid trials prompt deals rush for Chinese ‘super me-too’ drugs
- Fierce Biotech - 'People are getting used to it': Global uncertainties can't dampen upbeat Jefferies conference
- Forbion Co-Leads Oversubscribed $130 Million Series B Financing in Protego Biopharma
- VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
-
Insights
- The Biotech Pulse S1E1 - The Manufacturing of Complex Biologics
- The Biotech Pulse S1E2 - Navigating the M&A Landscape for Biotech Success
- The Biotech Pulse S1E3 - "Empowering Women's Health: A Conversation with Mary Kerr, CEO of NeRRe Therapeutics"
- The Biotech Pulse S1E4 - the role of biotech as the ‘discovery engine’ for pharma
- The Biotech Pulse S1E5 - Biotech Innovations and Sustainability
- The Biotech Pulse S1E6 - Advancing Women's Health: Bridging Gaps in Innovation and Action
- The Biotech Pulse S1E7 - Trust, Translation, and Therapeutics: The Story of Complement Therapeutics
- Get to know Forbion
- Our role in the rare diseases market
- Forbion's history in the development of gene therapies
- Our investment approach for companies developing precision treatments for rare diseases
- Special Event with the Cambridge Judge Business School “Smart Capital, Leveraged Science: How VCs Unlock Biotech Potential"
- The Biotech Pulse S1E8 - Special Edition with Cambridge Judge Business School: Smart Capital, Leveraged Science: How VCs Unlock Biotech Potential
- Bloomberg Vanguards of Health - Inside Forbion’s M&A-First Playbook for Building Europe’s Biotech Winners
- WXPRESS Interview with Forbion General Partner Marco Boorsma, PhD
-
Events
- The 2025 Cell & Gene Meeting on the Med
- Invest Europe: Sustainability in a changing geopolitical landscape: what you need to know
- 18th Annual European Life Sciences CEO Forum
- IPEM
- SACHS Associates - 1st BioPharma Obesity Innovation Forum for Science, Drug Development, Technology and Investment
- Dutch Life Sciences Conference - Leiden
- World Agri-Tech Innovation Summit
- Nordic Life Science Days - NLS Days 2024
- 10th LSX World Congress
- Swiss Biotech Day 2024
- Anglonordic Life Science Conference
- 0100 Conference Europe 2024
- Bio-Europe Spring 2024
- 17th Annual European Life Sciences CEO Forum For Partnering & Investment
- Bio-Neuroscience
- IPEM Cannes 2024
- Nordic Life Science Days
- Jefferies 2023 London Healthcare Conference
- Inv€$tival Showcase
- BioEurope Fall
- The ESMO Conference
- International Partnering, Strategy & Investment for Nordic Life Science Executive Leaders (LSX)
- 23rd Annual Biotech in Europe Forum
- SACHS Forum
- IPLS Amsterdam Future Life Cycles
- LSX Congress USA
- On the Road Amsterdam 2023
- Bio€quity Europe 2023
- LSX World Congress 2023
- Economist Impact - Cell and Gene Therapy Summit
- BioVaria Munich
- Swiss Biotech Day
- Anglo Nordic Life Science Conference
- Innovation for Health 2023
- Interact 2023 - Science & Translation
- Bio-Europe Spring
- The 16th Annual European Life Sciences CEO Forum
- Forbion Managing Partner Geert-Jan Mulder is guest speaker at the Talentmark Leiden office opening
- BioFIT
- Dutch Life Sciences Conference
- World Orphan Drug Congress 2022
- Inv€$tival Showcase 2022
- NVP Seminar VUCA-World (Volatility, Uncertainty, Complexity, Ambiguity)
- Onco Cell Therapy Summit Europe 2022
- BioEurope
- High-Tech Gründerfonds 7th Life Science Pitch Day
- 22nd Annual Biotech in Europe Forum for Global Partnering & Investment
- IPEM 2022
- European Forum
- LSX Nordic Congress
- Retina Forum
- Advanced Therapies Europe
- 8th Annual LSX World Conference
- Venture Challenge
- Global Investor Forum - Grow, Present, Connect
- 5th Annual Neuroscience Innovation Forum for Business Development, Licensing & Investment
- 15th Annual European Life Sciences CEO Forum
- LSX World Conference
- 3rd Annual Goodwin & KPMG JPMorgan Symposium
- The Next Frontiers in Tackling Age-Related Disorders
- Redefining Early Stage Investments (RESI) conference
- Super Return International
- Life Sciences Tuesdays
- LSX Inv€$tival Showcase
- Venture Capital Forum 2021
- European Biopharma Summit
- BIO-Europe 2025
- Women’s Private Equity Summit Europe 2025
- BioCentury Grand Rounds – Europe
- FRAME 2025
- IPEM Paris 2025
- 25th Annual Biotech in Europe Forum
- Venture Capital Forum 2025
- Climate Week NYC
- SuperReturn CFO/COO 2025
- Nordic Life Science (NLS) Days 2025
- European Society of Medical Oncology (ESMO) 2025
- ILPA Summit 2025
- Super Return Europe 2025
- Private Equity Insights 2025
- Media resources
-
News
- Contact
- Privacy policy
- Terms & conditions
- Grievances
- Page Not Found
- Search
- RSS
- Sitemap
- Sitemap XML
- Cookie policy